Abstract
Numerous photosensitizers have been developed and evaluated in China. HiPorfin, a hematoporphyrin derivative (HpD) received the first regulatory approval in the early 2000s. Aila, a topical formulation containing predrug 5-aminolevulinic acid, received the regulatory approval in 2007. Recently, new drug applications have been filed for several hematoporphyrin derivatives and a zinc phthalocyanine (ZnPc) derivative. This short report will summarize the current regulatory status of Chinese photosensitizers developed for photodynamic therapy (PDT).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
